-
Diagnostics World News | No cure or established early-stage detection method for Parkinson's disease has been found yet. Patients do not receive a diagnosis until motor symptoms begin to appear. A team of researchers from Chalmers University of Technology, Sweden and Oslo University Hospital, Norway have found a way to identify early signs of Parkinson’s disease in the blood.
Feb 5, 2026
-
Diagnostics World News | Soley Therapeutics will advance its proprietary cell stress sensing platform; Precede Biosciences’s platform aims to meet rapidly growing demand from developers of next-generation precision medicines; Proxima will accelerate the advancement of first-in-class proximity-modulating therapeutics; and more.
Feb 3, 2026
-
Diagnostics World News | Soley Therapeutics will advance its proprietary cell stress sensing platform; Precede Biosciences’s platform aims to meet rapidly growing demand from developers of next-generation precision medicines; Proxima will accelerate the advancement of first-in-class proximity-modulating therapeutics; and more.
Jan 28, 2026
-
Diagnostics World News | NeuroQure has launched ASD Insight, a first-of-its-kind test designed to identify autism risk as early as birth; Cytespace expanded its molecular testing to meet increasing demands across Sub-Saharan Africa; Daisy Genomics and New Day Diagnostics have entered a collaboration with the University of Tennessee and the East Tennessee Health Innovation Alliance; and more.
Jan 27, 2026
-
Diagnostics World News | A lot is at stake in obesity drug development, heightening the focus of pharma sponsors on producing the right evidence to support a label claim and differentiating their products in the rapidly growing weight management pharmacotherapy market. It’s also the rationale for the industrywide DECODE Obesity initiative of Ametris (formerly ActiGraph) looking to expand the range of outcome measures beyond weight loss.
Jan 23, 2026
-
Diagnostics World News | Illumina has announced CMS reimbursement for TruSight Oncology Comprehensive. The FDA-approved comprehensive genomic profiling test will be reimbursed at a rate of $2,989.55 per test. The news comes just a week after presenting a clinical-focused vision and strong Q4 results at the J.P. Morgan Healthcare Conference.
Jan 21, 2026
-
Diagnostics World News | There can be little debate that Alzheimer’s disease is one of the greatest healthcare challenges we face globally. Most recent estimates suggest that over 57 million people worldwide are living with dementia, of which 70% is caused by Alzheimer’s. With aging societies, this number is expected to increase to over 150 million by 2050. Yet there is a growing sense of impending change, particularly because the way we diagnose Alzheimer’s is now at a pivotal moment.
Jan 20, 2026
-
Diagnostics World News | Diagnostics took center stage at the 44th Annual J.P. Morgan Healthcare Conference this week, and even companies not formally presenting at the event timed announcements to highlighting new products and readouts from recent studies.
Jan 16, 2026